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Progressive microcephaly is a heterogeneous condition with causes including mutations in genes encoding regulators of neuronal sur-
vival. Here, we report the identification ofmutations inQARS (encoding glutaminyl-tRNA synthetase [QARS]) as the causative variants in
two unrelated families affected by progressive microcephaly, severe seizures in infancy, atrophy of the cerebral cortex and cerebellar ver-
mis, and mild atrophy of the cerebellar hemispheres. Whole-exome sequencing of individuals from each family independently identi-
fied compound-heterozygous mutations in QARS as the only candidate causative variants. QARSwas highly expressed in the developing
fetal human cerebral cortex in many cell types. The four QARSmutations altered highly conserved amino acids, and the aminoacylation
activity of QARS was significantly impaired in mutant cell lines. Variants p.Gly45Val and p.Tyr57His were located in the N-terminal
domain required for QARS interaction with proteins in the multisynthetase complex and potentially with glutamine tRNA, and recom-
binant QARS proteins bearing either substitution showed an over 10-fold reduction in aminoacylation activity. Conversely, variants
p.Arg403Trp and p.Arg515Trp, each occurring in a different family, were located in the catalytic core and completely disrupted QARS
aminoacylation activity in vitro. Furthermore, p.Arg403Trp and p.Arg515Trp rendered QARS less soluble, and p.Arg403Trp disrupted
QARS-RARS (arginyl-tRNA synthetase 1) interaction. In zebrafish, homozygous qars loss of function caused decreased brain and eye
size and extensive cell death in the brain. Our results highlight the importance of QARS during brain development and that epilepsy
due to impairment of QARS activity is unusually severe in comparison to other aminoacyl-tRNA synthetase disorders.Introduction
Microcephaly refers to a condition in which an individual’s
head circumference is significantly smaller than expected
for age and gender, and it can manifest either congenitally
or in early childhood.1–3 Autosomal-recessive primary
microcephaly (MCPH) refers to congenital microcephaly
with mild to moderate intellectual disability, relatively
normal height, weight, appearance, and brain scan, and
no other neurological findings.1 MCPH maps to at least
nine genomic loci, and all reported causative mutations
for MCPH are in genes that encode proteins associated
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The AmMCPH is caused by deficient mitosis of neural precur-
sors.4 In contrast to MCPH, progressive microcephaly asso-
ciated with diffuse cerebral-cerebellar atrophy represents
a large collection of heterogeneous conditions and accom-
panies various neurodegenerative diseases.2,3 Genetic
causes of progressive microcephaly tend to associate with
defects in gene transcription5 or protein translation (see
below). Progressive microcephaly with diffuse cerebral-
cerebellar atrophy is classified as pontocerebellar hypo-
plasia (PCH) in cases in which the brain stem and pons
are primarily affected.6 Out of eight genes previously
reported to have causative mutations for progressive
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or involved in protein synthesis; of these five, three
(TSEN54 [MIM 608755], TSEN2 [MIM 608753], and
TSEN34 [MIM 608754])7 encode regulators of tRNA
splicing, and two (SEPSECS [MIM 613009] and RARS2
[MIM 611524])8,9 encode enzymes for aminoacyl-tRNA
formation.
Aminoacyl-tRNA synthetases (aaRSs) attach amino acids
precisely to the correct tRNAs to maintain translational
fidelity.10 There are 37 aaRSs encoded by the human
genome: 18 of them function exclusively in the cyto-
plasm, 17 are localized in the mitochondria, and two are
bifunctional.11,12 The first connection between an aaRS
and human disease (Charcot-Marie-Tooth disease type
2D [MIM 601472] and distal spinal muscular atrophy
type V [MIM 600794]) was identified a decade ago,13
and since then, disease-causing mutations have been
reported in over a dozen aaRS-encoding genes.14,15 Muta-
tions in mitochondrial aaRS2-encoding genes have been
associated with a variety of human diseases,14,16 including
mitochondrial myopathy (YARS2 [MIM 610957]),17 senso-
rineural deafness (HARS2 [MIM 600783] and LARS2 [MIM
604544]),18,19 spastic ataxia with leukoencephalopathy
(MARS2 [MIM 609728]),20 and PCH with progressive
cerebral atrophy (RARS2).9,21 In contrast, mutations in
cytoplasmic aaRS-encoding genes14,16 are mainly associ-
ated with neurodegeneration of the peripheral nervous
system or brain stem and spinal cord, such as in
Charcot-Marie-Tooth neuropathies (GARS [MIM 600287],
YARS [MIM 603623]), AARS [MIM 601065], and
KARS [MIM 601421]),13,22–24 spinal muscular atrophy
(GARS),13 brain stem and spinal cord hypomyelination
(DARS [MIM 603084]),15 and nonsyndromic hearing loss
(KARS).25 The surprisingly diverse human diseases associ-
ated with mutations in aaRS-encoding genes suggest
diversified functions of individual aaRSs and mutant
alleles and an exciting but poorly understood biology of
protein translation during both development and degen-
eration of the human nervous system.
Here, we report a syndrome in two unrelated families
characterized by progressive microcephaly, intractable
seizures in infancy, diffuse atrophy of the cerebral cortex
and cerebellar vermis, and considerably mild atrophy of
the cerebellar hemispheres. We performed whole-exome
sequencing in both families and identified mutations in
QARS (glutaminyl-tRNA synthetase [MIM 603727]), encod-
ing QARS, which functions in the cytoplasm, as the causa-
tive variants. Mosaic analyses in Drosophila have shown
that QARS function is required for the dendritic and axonal
terminal arborization during development,26 but no
connection between QARS and human disease has been
previously reported.We show that all four variants severely
impaired QARS aminoacylation activity and that two sub-
stitutions appeared to make QARS susceptible to abnormal
aggregation. Zebrafish homozygous mutants carrying a
qars loss-of-function allele displayed small brain and
neurodegenerative phenotypes similar to those of the
human individuals carrying mutations in QARS. The548 The American Journal of Human Genetics 94, 547–558, April 3, 2distinctive features of loss of QARS activity in comparison
to those of loss of other aaRSs highlight the essential and
unique role of QARS during human and vertebrate brain
development.Material and Methods
Human Studies
All human protocols were reviewed and approved by the
institutional review board of Boston Children’s Hospital, Hoˆpital
Necker–Enfants Malades, and related local institutions. Informed
consent was obtained from all subjects involved in this study or
from parents of those who were less than 18 years old.Whole-Exome Sequencing and Sanger Validation
For family I (MC30500, USA), DNAwas extracted from peripheral-
blood leukocytes, and genomic DNA was subjected to array
capture with the SureSelect Human Exon Kit (Agilent Technolo-
gies) according to the manufacturer’s instructions. Adapters were
ligated, and 2 3 76 bp paired-end sequencing was performed on
an Illumina HiSeq 2000 at the Broad Institute, producing for
each sample ~10 Gb of sequence covering 86% of the target
sequence at least 20 times. Sequencing reads were aligned to the
reference human genome (hg19, UCSC Genome Browser) with
the Burrows-Wheeler Aligner (v.0.5.7), consensus and variant
bases were called with the Genome Analysis Toolkit, and variants
were annotated with ANNOVAR. Annotated variants were entered
into a MySQL database and filtered with custom queries.27
For family II (MC34900, France), DNA extracted from blood
samples was captured with the SureSelect Human All Exon v.2
Kit (Agilent Technologies). Paired-end sequencing was carried
out on an Illumina HiSeq 2000, which generated 100 bp reads.
For each sample, 6–8 Gb of sequence was produced. The mean
exome coverage was 52-fold, and 82% of the target sequence
was covered at least 15 times.
To validate c.134G>T (p.Gly45Val), we amplified individual
genomic DNA samples with primer pair CH91 and CH92 and
Sanger sequenced them with CH90 and CH92 (see Table S1,
available online, for oligonucleotide sequences). To validate
c.1207C>T (p.Arg403Trp), we amplified individual genomic
DNA samples with primer pair CH93 and CH94 and Sanger
sequenced them with CH87 and CH93. To validate c.1543C>T
(p.Arg515Trp) and c.169T>C (p.Tyr57His), we amplified genomic
DNA samples and Sanger sequenced them with KCNT1-Ex1/2 F
and R and KCNT1-Ex16/17 F and R, respectively.Molecular Cloning
Wild-type (WT) human QARS coding sequence was PCR amplified
from a cDNA clone (RefSeq accession number NM_005051.2,
Origene SC320264) with primer pair CH379 and CH380 (see Table
S1 for oligonucleotide sequences), cut with KpnI and XhoI, and
ligated into pCDNA3.1A(þ) for the generation of pCDNA3.1-Myc-
FLAG-hsQARS-WT. Point mutations c.134G>T, c.1207C>T,
c.169T>C, and c.1543C>T were introduced with the Quick-
Change II XL Site-Directed Mutagenesis Kit (Agilent) with primer
pairs CH188 and CH189, CH190 and CH191, CH381 and CH382,
CH383 and CH384, respectively. Equal amounts of five hsQARS
expression vectors were transfected into Neuro2a cells (ATCC) or
Cos7 cells (ATCC) with Lipofectamine 2000 (Life Technologies)
for protein studies.014
Immunoblotting, Coimmunoprecipitation,
Immunostaining, and Microscopy
For immunoblotting, resuspended cell pellets were mixed with
RIPA buffer (Pierce) and protease inhibitors (cOmplete Mini,
Roche) and proteins were extracted. Immunoblots were carried
out according to standard protocols. Protein immunoblots were
scanned on a Li-Cor Odyssey imager.
For coimmunoprecipitation (coIP), recombinant Myc-FLAG-
QARS proteins were transiently produced in human embryonic
kidney 293T (HEK293T) cells (supplemented with 2.5mM L-gluta-
mine) and extracted with immunoprecipitation (IP) buffer
(25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1%
NP-40, and 5% glycerol supplemented with protease and phos-
photase inhibitors [cOmplete Mini and PhosStop, Roche]). Cell ly-
sates were cleared by centrifugation at 16,000 3 g for 20 min at
4C. Ten percent of the supernatant was saved as input, and the
rest was incubated overnight with 20 ml anti-FLAG (M2) magnetic
beads (Sigma-Aldrich) at 4C. The beads were washed four times
with 800 ml IP solution and boiled in 65 ml 13 laemmli SDS-
PAGE loading buffer for 5 min. Eluted fractions, along with corre-
sponding inputs, were subjected to SDS-PAGE and immunoblot.
Immunostaining was carried out according to standard proto-
cols.28 Antigen retrieval (BD Retrievalgen) was performed on para-
formaldehyde-fixed cryosections before staining. Alexa secondary
antibodies (Life Technologies) were used, and all slides were
counter stained with Hoechst33342. TUNEL (terminal deoxynu-
cleotidyl transferase dUTP nick-end labeling) assays were per-
formed according to the manufacturer’s instructions (Click-iT,
Life Technologies). Images were taken with an AxioVision
confocal microscope (Zeiss) and processed with Adobe Photoshop
CS5 and Illustrator CS5.
Antibodies used in this study include anti-QARS (SAB1406358,
Sigma), anti-FLAG (M2, F3165, Sigma-Aldrich; 2368, Cell Sig-
naling), anti-aTubulin (ab18251, Abcam), anti-Sox2 (sc-17320,
Santa Cruz), anti-ERp72 (5503, Cell Signaling), anti-RCAS1
(11290, Cell Signaling), anti-phospho-histone H3 (H9908,
Sigma-Aldrich), anti-Pax6 (PRB-278P, Covance), anti-HuC/D
(A-21271, Life Technologies), anti-ASK1 (ab45178, Abcam), and
anti-RARS (ab31537, Abcam).Production and Purification of Recombinant Human
QARS Proteins
Human QARS was codon optimized for E. coli strains (GeneArt)
and cloned between NheI and XhoI sites of pET28a for the gener-
ation of an N-terminal His-tagged fusion protein with the use of
the In-Fusion PCR Cloning System (Clontech). Point mutations
c.134G>T, c.1207C>T, c.169T>C, and c.1543C>T were intro-
duced with the QuickChange mutagenesis method. pET28a
plasmids with WT QARS and mutant alleles were transformed
into the Rosetta pLysS strain. QARS production was induced in
cells that were growing in Terrific Broth II (MP) by 0.1 mM IPTG
at 16C overnight.
For purification of QARS proteins, cells from 500ml culture were
resuspended in 50ml binding buffer (25 mMTris, pH 8.0, 500mM
NaCl, 10% glycerol, 5 mM 2-mercaptoethanol, 0.1% Triton X-100,
and 20 mM imidazole) and lysed by sonication. Cell lysate was
clarified by centrifugation at 16,000 3 g for 30 min. The superna-
tant was incubated with 1 ml Ni Sepharose High Performance
beads (GE) at 4C for 1 hr. The beads were washed with 50 ml
wash buffer (25mMTris-HCl, pH 8.0, 500mMNaCl, 10% glycerol,
5 mM 2-mercaptoethanol, 0.1% Triton X-100, and 50 mMThe Amimidazole) and eluted with a 10 ml elution buffer (25 mM Tris-
HCl, pH 8.0, 500 mM NaCl, 10% glycerol, 5 mM 2-mercapto-
ethanol, 0.1% Triton X-100, and 250 mM imidazole). Eluted
fractions were analyzed by SDS-PAGE, concentrated, and dialyzed
twice against 1 liter of buffer (25 mM Tris-HCl, pH 8.0, 300 mM
NaCl, 10% glycerol, and 5 mM 2-mercaptoethanol). Dialyzed
proteins were used in aminoacylation activity assays.
Cell-Line Generation and Aminoacylation Assay
Immortalized lymphoblastoid cell lines were generated by trans-
duction of individual blood samples with Epstein-Barr virus
according to standard protocols. Lymphoblastoid cell lines were
maintained in RPMI1640 medium supplemented with 10% fetal
bovine serum and antibiotics. Cells were collected, washed in
13 Dulbecco’s phosphate-buffered saline, and lysed in 50 mM
Tris-HCl, pH 7.5, 150 mMNaCl, 5 mM dithiothreitol, 0.5% Triton
X-100, and a protease inhibitor at 4C for 20 min. Cell debris were
removed by centrifugation at 10,0003 g for 15 min. Total-protein
concentration was determined with the bicinchoninic acid
protein assay (Pierce) as described in the manufacture’s protocol.
Then, 0.25–0.38 mg/ml of total protein was incubated with
5 mM human cytoplamic tRNAGln transcripts, 2 mM ATP, and
50 mM [3H] Gln (320 cpm/pmol) in 100 mM HEPES-NaOH, pH
7.2, 30 mMKCl, and 10 mMMgCl2 at 37
C. Aliquots were spotted
on 3MMWhatman paper discs presoaked with 5% trichloroacidic
acid (TCA), washed three times with 5% TCA, dried, and scintilla-
tion counted.
Zebrafish Protocols
Zebrafish were maintained according to animal research guide-
lines at Boston Children’s Hospital. The qars mutant fish strain
was generated by random insertion of a gene-trap cassette through
retroviral infection of fish embryos.29 Insertion of the gene trap
into the first intron of qars was confirmed by PCR amplification
and Sanger sequencing.29 Fish genotypes were identified by PCR
with primer pair CH184 and CH185 for the WT allele (350 bp)
and with primer pair CH184 and CH186 for the mutant allele
(315 bp).29 Male and female heterozygous fish were bred to each
other, and their progeny’s tails were cut off at 2, 3, or 6 days
postfertilization (dpf) for genotype determination. Fish heads of
the same genotype were immediately fixed, pooled together after
genotyping, and further processed for bright-field measurements,
whole-mount staining, or cryosectioning. Images were taken on
Zeiss microscopes, and eyes and brains were measured with
AxioVision (Zeiss). Statistical analyses were carried out with
GraphPad Prism.Results
Clinical Findings in Two Families Affected by
Progressive Microcephaly and Severe Epilepsy
Brothers I-1 and I-2 (family I, MC30500, Figure 1A), aged 5
years and 4 years, respectively, are from a European
American nonconsanguineous family. Their key pheno-
typic features are presented here, and additional details
are reported in Table S2. Their mother has Raynaud disease
and scleroderma (MIM 613471), and their father has atten-
tion deficit hyperactivity disorder (MIM 143465). Neither
parent has any history of neurological problems. The elder
brother (I-1) was born at 38 weeks of gestation by normalerican Journal of Human Genetics 94, 547–558, April 3, 2014 549
Figure 1. Microcephaly and Neurodegeneration in Two Nonconsanguineous Families and the Identification of QARS Mutations
(A) Pedigrees of microcephaly-affected families I (A) and II (B). Shaded symbols indicate individuals affected bymicrocephaly and diffuse
cerebral-cerebellar atrophy.
(B) T1-weighted sagittal (top) and axial (bottom) brain MRI of normal and affected individuals. Common findings across the four
affected individuals included microcephaly, enlarged subarachnoid space, enlarged lateral ventricles, thin corpus callosum, atrophy
in cerebral cortex, and cerebellar vermis. Note that individuals I-1and I-2 displayed severely simplified gyral patterns and decreased
contrast of white and gray matter. The individuals’ ages at examination are as follows: normal control, 2 years 8 months; I-1, 4 years
3 months; I-2, 3 years 1 month; II-1, 6 months; II-1, 5 years 4 months; and II-2, 3 years 7 months.
(C) Sanger sequencing traces confirmed that theQARS compound-heterozygousmutations in affected children were inherited separately
from their mother (c.134G>T for family I; c.1543C>T for family II) or father (c.1207C>T for family I; c.169T>C for family II) and that
the unaffected brother (I-5) did not have the c.134G>T mutation. Positions of variants are indicated on the genome (hg19), cDNA
(RefSeq NM_005051.2), and protein (RefSeq NP_005042.1).
(D) Human QARS (RefSeq NP_005042.1) and E. coli GlnRS (RefSeq YP_488960.1) domains predicted by the NCBI and variants are
indicated by red arrows.
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spontaneous vaginal delivery (NSVD). At birth, he was
noted to have a sloping forehead, an occipitofrontal
circumference (OFC) of 27.9 cm (3.5 SDs; below the
mean for his age), normal height (50th percentile), and
normal body weight (12th percentile). Individual I-1
showed severe developmental delay, and by 21 months
of age, his OFC was 34 cm (10.4 SDs below the mean),
his height was 77 cm (2.3 SDs below the mean), and
his weight was 7.8 kg (3.8 SDs below the mean).
Individual I-2 was noted to have microcephaly at
29 weeks of gestation and was born by NSVD at full
term. At birth, he also had a sloping forehead, an OFC of
31.1 cm (2.1 SDs below the mean), normal height (41th
percentile), and normal body weight (25th percentile). He
also exhibited profound developmental delay, and by
7months of age, his OFCmeasured 34 cm (7.8 SDs below
the mean), his height was 63.5 cm (2.1 SDs below the
mean), and his weight was 6.6 kg (2.1 SDs below the
mean).
The elder brother (I-1) had seizure onset within the first
hour of life and had hundreds of seizures per day and
pharmacoresistant status epilepticus (SE). When he was
4 months of age, clinical reports showed 10–20 seizures
per hour and persistent SE (epileptic episodes could last
10–12 hr). The seizures were described as either generalized
tonic or focal clonic with either the right or the left side of
the body involved and were accompanied by unrespon-
siveness. Trials of phenobarbital, levetiracetam, lorazepam,
topiramate, oxcarbazepine, valproic acid, gabapentin,
lamotrigine, and clonazepam were ineffective in control-
ling the seizure activity. At 18 months of age, twice per
hour, he was noticed to have seizures with apnea lasting
30–60 s each time. Individual I-2 also had seizures on the
first day of life; they were frequent, recurrent, and long
lasting. He did not have electroencephalography (EEG)
recordings and did not receive medication before 2 years
of age because of parental preference and the lack of
efficacy of seizure control in his brother. Individual I-2
was treated with clonazepam and gabapentin regularly
for seizures after 2 years of age.
Notably, at 3 years of age, individual I-1 experienced a
4-month period of illness during which he was reported
to have episodes characterized by sudden onset of constant
kicking and thrashing, dehydration, pneumonia, and rhab-
domyolysis with a peak creatine kinase level of >7,000 u/l.
He had another similar period lasting 3months around the
age of 3.8 years. The younger brother (I-2) experienced
similar episodes lasting 2 months at the age of 2 years
and another one lasting 8 months at the age of 3 years.
These episodes were marked by extreme agitation (espe-
cially when touched), sensitivity to sound, excessive
sweating, arching, stiffness, swollen and puffy feet, thin-
ning hair, hematemesis, and little to no sleeping. During
these periods, the usual seizures were notably absent.
Individuals II-1 and II-2 (family II, MC34900, Figure 1A)
are brother and sister and were born to healthy non-
consanguineous French parents of European descent. TheThe Amelder brother (II-1) was born at 41 weeks of gestation after
an uneventful pregnancy. At birth, he showed an OFC
at 1 SD, normal body weight (tenth percentile), and
normal height (51st percentile). Seizures started in the first
hour of life and consisted of clonic movements of the right
hemiface and lower limbs, drooling, and cyanosis. Seizures
were polymorphic, long lasting, and pharmacoresistant.
Ictal EEG showed a ‘‘migrating’’ pattern consistent with
migrating partial seizures in infancy. He showed global
hypotonia and lack of visual interaction. At 5.5 years of
age, he showed profound psychomotor delay and micro-
cephaly (3 SDs) and had active epilepsy with weekly
seizures that were resistant to antiepileptic drugs (AEDs).
The sister (II-2) was born at full term after an uneventful
pregnancy and delivery. She had an OFC of 32 cm (1 SD),
normal height (40th percentile), and normal body weight
(11th percentile). She started to have epilepsy at the age
of 1 month, and her first seizures were clonic with apnea
and cyanosis. Clusters of focal polymorphic seizures then
occurred about twice per month and were poorly con-
trolled despite many AED trials. When she was 5 months
of age, seizures occurred in clusters of 20–30 several times
per day. Clinical manifestations were variable but were
often mild and accompanied by eye deviation, chewing,
apnea, and cyanosis. Ictal EEG showed migrating focal sei-
zures.When she was 15months of age, her head circumfer-
ence was below the third percentile and she had severe
hypotonia with global psychomotor delay. At 3 years of
age, she had weekly seizures, failed to gain further develop-
mental skills, and had microcephaly (2.5 SDs).
Neuroimaging Features of the Two Families
Brain MRI (Figure 1B) showed that by 5 years of age, the
four affected children displayed very similar features,
including microcephaly secondary to apparent neurode-
generation, hypomyelination or delayed myelination,
thin corpus callosum and reduced white matter, moder-
ately enlarged cerebral ventricles, small cerebellar vermis,
and mild atrophy of the cerebellar hemispheres. Individ-
uals I-1 and I-2 displayed more severe microcephaly
(present at birth) and fewer gyral folds than did individuals
II-1and II-2. In individual II-1, who had serial imaging,
there was a marked increase in ventricular size and extra-
axial fluid, suggesting that progressive atrophy had
occurred in the interval between 6 months and 5 years.
The syndrome is hereafter referred to as progressive micro-
cephaly with diffuse cerebral-cerebellar atrophy.
Clinical Genetic Evaluation for Epilepsy and
Microcephaly
Individuals I-1 and I-2 were evaluated with comparative
genomic hybridization (CGH) arrays (Agilent) and SNP
arrays (Affymetrix), but no clinically significant abnormal-
ities in copy number or long continuous stretches of
homozygosity were identified. Sequences of TUBA1A
(MIM 602529), DCX (MIM 300121), LIS1 (MIM 607432),
and ARX (MIM 300382), known genes that might haveerican Journal of Human Genetics 94, 547–558, April 3, 2014 551
causative mutations for lissencephaly, were normal. For
individual II-1, karyotype, CGH array, and sequencing of
mitochondrial genes were all normal. Metabolic screening
and studies of respiratory chain enzymes on muscle and
liver did not identify a cause for the child’s condition.
Sequencing of KCNT1 (MIM 608167), mutations in which
cause migrating partial seizures,30 did not reveal any
mutation.
Identification of QARS Mutations through
Whole-Exome Sequencing
To identify the causative mutation(s) for individuals I-1
and I-2, we subjected genomic DNA samples from both
affected children to whole-exome sequencing (WES) and
aligned the sequencing reads to the reference human
genome (see the Material and Methods for more details).
We analyzed WES results under a recessive inheritance
model, and the fact that no shared homozygous mutations
were identified between the brothers is consistent with
their parents’ nonconsanguinity. We then looked for
possible compound-heterozygous mutations shared by
individuals I-1 and I-2. After we filtered out variants that
were noncoding, synonymous, and of low quality and
had a high allele frequency in 1000 Genomes or the spe-
cific batch of sequenced samples, QARS and CFTR (cystic
fibrosis transmembrane conductance regulator [MIM
602421]) were the only two candidate genes that
remained. Because CFTR mutations are not associated
with epilepsy and because the level of immunoreactive
trypsinogen was normal at birth in individual I-1,
we excluded CFTR and focused on QARS. Direct Sanger
sequencing confirmed that the QARS mutations
(c.134G>T [p.Gly45Val] and c.1207C>T [p.Arg403Trp])
were separately inherited from each parent and that the
unaffected sibling inherited only one of these alleles
(Figure 1C). These data suggest that the compound-hetero-
zygous mutations in QARS are causative for the micro-
cephaly and neurodegeneration symptoms.
For family II, blood DNA samples from both affected
children and their parents were subjected to WES. Variants
were filtered similarly as for family I (see the Material and
Methods for details). We identified two compound-hetero-
zygous missense variants (c.169T>C [p.Tyr57His] and
c.1543C>T [p.Arg515Trp]) in QARS in both siblings,
supporting the hypothesis of a recessive mode of inheri-
tance. Both variants were confirmed by Sanger sequencing
and were found to be inherited either from the father
(c.169T>C) or from the mother (c.1543C>T) (Figure 1C).
In addition, the two affected children also carried
an apparent de novo missense variant (c.55G>A
[p.Ala19Thr]) in ATP5G2 (MIM 603193), but Sanger
sequencing revealed that this variant was actually
inherited from the healthy father and was thus not further
studied. No other novel variant compatible with a recessive
or dominant mode of inheritance was identified.
Notably, none of the four parents had any history of
neurological problems at the time of examination (I-3 at552 The American Journal of Human Genetics 94, 547–558, April 3, 2the age of 28 years, I-4 at 30, II-3 at 29, and II-4 at 43).
Given the early age of onset for dominant phenotypes
associated with other aaRSs,13,22 these healthy parents
preclude the possibility that QARS-mutation-associated
diseases are dominantly inherited.
QARS encodes QARS, a component of the multisyn-
thetase complex (MSC) in human cells.31 All four variants
(p.Gly45Val, p.Tyr57His, p.Arg403Trp, p.Arg515Trp) alter
residues that are highly conserved across vertebrate and
plant species, and Arg403 and Arg515 are conserved across
the phylogenetic tree to yeast and bacteria (Figure S1). Var-
iants p.Gly45Val and p.Tyr57His, each occurring in a
different family, are located in the N-terminal domain
that interacts with other aaRSs in the MSC32 and
potentially interacts with glutamine tRNA,33 whereas
p.Arg403Trp and p.Arg515Trp, also each occurring in a
different family, reside in the aminoacylation catalytic
domain (Figure 1D). All four amino acid substitutions are
predicted to be damaging to protein function (Table S3).
QARS Is Widely Expressed in Fetal Human Brain
during Early Development
To understand the function of QARS in the human brain,
we analyzed published RNA-sequencing (RNA-seq) data34
on fetal human cerebral cortex and found that QARS
mRNA was highly expressed and evenly distributed in
the ventricular zone (VZ), inner subventricular zone
(ISVZ), outer subventricular zone (OSVZ), and cortical
plate (CP) (Figure 2A). Immunostaining on gestational
week 15 normal fetal human brain sections showed high
levels of QARS immunoreactivity in the VZ, ISVZ, OSVZ,
and CP (Figure 2B and data not shown). Endogenous
QARS wasmainly distributed in the cytoplasm and showed
a similar localization pattern to an endoplasmic reticulum
(ER) protein, but not a Golgi protein (Figure S2A). Recom-
binant WT human QARS showed similar subcellular local-
ization to endogenous monkey QARS in Cos7 cells, but we
did not find any significant subcellular-localization change
when each of the four substitutions was introduced (data
not shown).
Aminoacylation Activity of QARS Is Disrupted
by Human Variants
To understand whether the function of QARS was impaired
in the affected individuals, we examined glutamine ami-
noacylation activities by using cell extracts from lympho-
blasts derived from human blood samples. We found that
QARS activity was significantly lower in cell lines of indi-
viduals carrying variants in both families and mildly lower
in cell lines derived from their parents than in normal con-
trol cell lines (Figure 3A–3C and Table 1). An initial amino-
acylation experiment in the presence of 150 mMNaCl and
0.05% Triton X-100 (Figure 3A) revealed no significant dif-
ference in QARS activities between individuals I-1 (affected
child) and I-3 (healthy mother). However, after passing the
cell extracts through a G25 desalting column, we observed
30% lower QARS activity in I-1 than in I-3 (Figure 3C),014
Figure 2. QARS Is Expressed in the Human Fetal Brain
(A) RNA-seq results from gestational week 15 (GW15) fetal human
cortices were extracted from published data sets34 with the
CummeRbund package in R. QARS was expressed at high levels
in the VZ, ISVZ, OSVZ, and CP. ASPM expression is shown as a con-
trol.35 Themean of fragments per kilobase of transcript permillion
mapped reads (FPKM)5 SD is presented.
(B) Anti-QARS immunostaining results on a section of GW15 fetal
human cerebral cortex showQARS amounts in the VZ and CP. The
scale bar represents 200 mm.suggesting that the additional variant (p.Arg403Trp) in I-1
is sensitive to misfolding at low salt concentrations.
To further explore the impact of individual human vari-
ants on QARS function, we purified each recombinant
QARS variant and tested their aminoacylation activity
(Figure 3D). Two variants (p.Arg403Trp and p.Arg515Trp)
occurring in the catalytic domain completely disrupted
QARS aminoacylation activity. The N-terminal domain
variants (p.Gly45Val and p.Tyr57His) decreased QARS ami-
noacylation activity to less than 10% of WT QARS activity.
Such a decrease in aminoacylation activity in the recombi-
nant altered QARS proteins appears to bemore drastic than
that in the cell extracts, possibly because QARS is more
stable in the cellular context. The addition of Triton
X-100 in the cell extracts might also increase the solubility
of altered QARS proteins. These results demonstrate that all
four human QARSmutations cause severe loss of function.
Substitutions p.Arg403Trp and p.Arg515Trp Decrease
Solubility of QARS
To determine whether reduced QARS aminoacylation
activity was caused by reduced protein production, we
directly tested QARS amounts in mutant cell lines. Immu-The Amnoblotting showed that QARS amounts in the soluble and
insoluble fractions of total protein were relatively normal
in individuals I-1, II-1, and II-2 in comparison to those of
their parents and control cell lines (Figure S2B).
To characterize individual variants, we cloned WT and
mutant human QARS cDNAs into expression vectors and
examined protein amounts in transiently transfected
mouse Neuro2a cells. Interestingly, p.Arg403Trp or
p.Arg515Trp altered QARS showed significantly reduced
amounts in the soluble portion of total protein and
increased amounts in the insoluble portion (Figure 4A).
These results suggest that p.Arg403Trp and p.Arg515Trp
might cause protein misfolding and aggregation.
Next, we analyzed the location of each variant by using
the crystal structure of E. coli glutaminyl-tRNA synthetase
(GlnRS),36 which is homologous to humanQARS.Whereas
the N-terminal domain of human QARS is absent from
bacterial GlnRS, the catalytic and anticodon domains of
human QARS are highly conserved in E. coli GlnRS
(Figure 1D). Human positions Arg403 and Arg515 were
mapped to E. coli Arg174 and Arg290, respectively. E. coli
Arg174 (equivalent to human Arg403) is within the
catalytic site, and E. coli Arg290 (human Arg515) is located
at the interface of the catalytic and anticodon domains
(Figure 4B). It is thus conceivable that these two Arg-to-
Trp substitutions would disrupt the domain structure and
overall folding of QARS.
Substitution p.Arg403Trp Disrupts the Interaction
between QARS and RARS
The N-terminal domain of human QARS has been reported
to directly interact with MARS, RARS, and IARS in the
MSC.37 To examine whether p.Gly45Val and p.Tyr57His
alter the interaction between QARS and MSC, we carried
out coIP assays between QARS and RARS, a component
of the MSC, in a HEK293T cell line. Although a clear inter-
action between WT QARS and RARS was detected, this
interaction was not significantly affected by p.Gly45Val
or p.Tyr57His (Figure 4C). However, the QARS-RARS
interaction was severely disrupted by p.Arg403Trp
(Figure 4C), suggesting again that the p.Arg403Trp change
alters QARS confirmation.
qars Mutant Fish Display Small Eyes and Brains
To better understand the role of qars during brain develop-
ment, we took advantage of a qars mutant fish that was
previously reported in a large-scale genetic screen.29 A
gene-trap cassette inserted into the first intron of qars is
predicted to truncate the qars transcripts.29 We generated
qars/ embryonic fish by breeding qarsþ/ pairs and iden-
tified them at the expectedMendelian ratio at both 2 and 6
dpf. qars/ fish demonstrated normal development up to
2 dpf, presumably because of compensation by maternal
effects. At 3 dpf, qars homozygous mutant (qars/) fish
displayed significantly smaller eyes and brains than did
their qarsþ/ and qarsþ/þ siblings (Figures 5A–5D). Also
starting from 3 dpf, qars/ fish were smaller and lesserican Journal of Human Genetics 94, 547–558, April 3, 2014 553
Figure 3. QARS Variants Impair tRNA
Synthetase Activity
(A and B) Aminoacylation activity of QARS
was lower in cell lines carrying compound-
heterozygous QARS mutations from
affected individuals I-1 (A) and II-1 and
II-2 (B) than in a normal control cell line.
Single substitution in p.Gly45Val (I-3),
p.Tyr57His (II-4), and p.Arg515Trp (II-3)
also impaired QARS aminoacylation
activity. Mean values5 SD are presented.
(C) Under a desalted condition, aminoacy-
lation activity of QARS was significantly
lower in individual I-1 than in his un-
affected mother (I-3). Mean values 5 SD
are presented.
(D) Recombinant QARS proteins were
individually induced in E. coli and purified,
and their aminoacylation activities are
presented. Enzyme activity was undetect-
able in the p.Arg403Trp and p.Arg515Trp
variants and was decreased to lower
than 10% of WT QARS by p.Gly45Val
and p.Tyr57His. Mean values 5 SD are
presented.pigmented than their qarsþ/ and qarsþ/þ siblings.
Compared to the well-balanced qarsþ/ and qarsþ/þ
siblings at 5 dpf, the majority of hatched qars/ fish
were lying laterally, and when touched, they swam briefly
in an unbalanced manner and settled down again on their
sides. The small brain and uncoordinated movement of
the qars/ fish show striking parallels to the human
symptoms.
Neurodegeneration in qars/ Fish Brains
To determine why qars/ fish displayed small eyes and
brains at 3 dpf, we examined neurogenesis and cell death
in both organs before and after the defects appeared. At
2 dpf, the number of mitotic cells was relatively normal
in qars/ brains and slightly decreased in qars/ eyes
(Figure S3). Also at 2 dpf, the number of apoptotic cells
in qars/ brains was comparable to that in qarsþ/ and
qarsþ/þ siblings (Figures 5E and 5G). In contrast, signi-Table 1. QARS Activity in Lymphoblast Cell Lines Derived from Healthy Controls and Individu
Individuals with QARS Variants
34901 34902 34903 34904 30501
QARS variants p.Tyr57His/
p.Arg515Trp
p.Tyr57His/
p.Arg515Trp
WT/
p.Arg515Trp
p.Tyr57His/
WT
p.Gly45Val/
p.Arg403Trp
Activity (nmol/min/mg)a 0.24 5 0.03 0.33 5 0.05 0.51 5 0.16 0.58 5 0.11 0.28 5 0.05
aQARS activity was calculated as nmol of product formation per min per mg of total protein from cell extrac
554 The American Journal of Human Genetics 94, 547–558, April 3, 2014ficantly more apoptotic cells were
detected in 6 dpf qars/ brains and
eyes than in those of their qarsþ/
and qarsþ/þ siblings (Figures 5E and
5F). These results indicate that exten-sive cell death occurs in qars/ brains and eyes at later
stages of development. The cell-death phenotype again is
consistent with the observations of progressive micro-
cephaly and diffuse atrophy in human individuals carrying
QARS mutations and suggests that QARS is essential for
neuronal survival.Discussion
Here, we have shown that loss-of-function mutations in
QARS, encoding QARS, cause a syndrome of progressive
microcephaly, intractable epilepsy in infancy, and diffuse
brain atrophy in which the cerebral cortex and cerebellar
vermis are most affected. Mutations were identified in two
unrelated families affected by similar phenotypes, and
loss of qars function in zebrafish caused strikingly similar
defects. Themutations described thus far were allmissense,als Carrying QARS Variants
Healthy Controls
30503 1403 2185
p.Gly45Val/
WT
WT/
WT
WT/
WT
0.41 5 0.08 0.83 5 0.15 0.79 5 0.19
ts. Mean values 5 SD are presented.
Figure 4. Effects of Individual Variants on QARS Solubility and Protein-Protein Interaction
(A) Immunoblot showing that the amounts of tagged p.Arg403Trp and p.Arg515Trp (anti-FLAG, green) were decreased in the superna-
tant (top) but increased in the pellet (middle). Rehybridization of the top membrane with anti-QARS (red) confirmed that p.Arg403Trp
and p.Arg515Trp reduced the amount of QARS in the supernatant (bottom). The anti-QARS antibodywas raised against humanQARS. In
the mouse cell line (Neuro2a), it detected recombinant human QARS, but not endogenous mouse QARS.
(B) E. coli Arg174 (equivalent to human Arg403, see Figure 1D) and Arg290 (equivalent to human Arg515) are shown on the 3D QARS
structure (Protein Data Bank ID 1ZJW).36
(C) Individual recombinant QARS variants and WT QARS were immunoprecipitated (mouse anti-FLAG, clone M2) from a human cell
line (HEK293T). Enrichment of recombinant proteins was confirmed by immunoblotting with a rabbit anti-FLAG antibody (red).
Consistent interaction between recombinant QARS and endogenous RARS (green) was observed with all but the p.Arg403Trp variants.and QARS variants were severely defective but appeared to
retain residual biochemical activity, suggesting the possibil-
ity that the knownmutations confer partial loss of function
and that complete loss of QARS function might be even
more severe, potentially lethal at birth or before.
GlnRS manifests as a monomer in E. coli38 and
S. cerevisiae,39 and QARS manifests as a component of the
MSC in human cells.40 The N-terminal domain of QARS
is suggested to interact with arginyl-tRNA synthetase in
the human MSC,37 and that of GlnRS contributes to the
binding of tRNAGln in yeast.33 We have shown that the
two variants (p.Gly45Val and p.Tyr57His) in the N-termi-
nal domain lead to an over 10-fold decrease in aminoacy-
lation efficiency (Figure 3C). However, the interactions
with RARS do not appear to be severely affected by
p.Gly45Val and p.Tyr57His, suggesting that the two vari-
ants might affect glutamine tRNA binding. Positions
Arg403 and Arg515 are located in the catalytic domain;
Arg403 is close to the tRNA acceptor binding site, and
Arg515 is at the interface between the catalytic and anti-The Amcodon domains (Figure 4B). It is highly likely that variants
in the catalytic domain disrupt the domain structures and
overall folding of QARS. In line with this notion, we
observed that QARS variants p.Arg403Trp and p.Arg515Trp
completely lost aminoacylation activity and appeared to
be less soluble than WT QARS (Figure 4A). The
p.Arg403Trp variant, but not p.Arg515Trp, disrupted the
interaction between QARS and RARS, further supporting
the idea of a protein conformation change (Figure 4C).
The fact that p.Arg403Trp was more deleterious than
p.Arg515Trp could relate to the more severe gyral defects
in individuals I-1 and I-2 than in individuals II-1 and II-2
(Figure 1B). These results, as well as the aminoacylation
activity tests on cell lines, suggest that all four individual
substitutions severely impair QARS functions and that a
fine threshold of QARS aminoacylation activity appears
to be critical for the disease onset.
QARS has been reported to have glutamine-dependent
antiapoptotic functions through binding to ASK1.41 To
test the possibility that the human variants might impairerican Journal of Human Genetics 94, 547–558, April 3, 2014 555
Figure 5. Neurodegenerative Pheno-
types in the Eyes and Brains of qars
Mutant Fish
(A and B) Bright-field images (A) and statis-
tical analysis (B) show that 3 dpf qars
mutant (/) fish displayed smaller eyes
than did their heterozygous (þ/) and
WT (þ/þ) siblings. The red bar and labeled
value (A, left) show how the eye lengths
were measured. Each dot (B) represents
onemeasurement of one eye, and horizon-
tal bars indicate the median values
(309.7 mm for þ/þ, 312.9 mm for þ/,
and 205.1 mm for /).
(C andD)Merged Z-stack nuclear stains (C,
blue, top view in left panel and lateral view
in right panel) and statistical analysis (D)
show that 3 dpf qars mutant fish had
smaller brains than their heterozygous
(þ/) and WT (þ/þ) siblings. The red
bar and labeled value counts (C, left)
show as an example how midbrains were
measured. Each dot (D) represents one
measurement of one brain, and horizontal
bars indicate the median values (139.3 mm
for þ/þ, 143.3 mm for þ/, and 87.4 mm
for /).
(E–G) TUNEL stains (E, red) and statistical
analyses (F and G) of 6 dpf (left) and 2
dpf (right) fish sections show extensive
cell death in qars mutant brains and eyes
at 6 dpf. The scale bars represent 100 mm.
Bar graphs (F and G) show that TUNEL-
positive cell amounts on each section
were higher in 6 dpf (F), but not 2 dpf
(G), qars mutant (/) brains than in
their þ/þ and þ/ siblings. Mean
values5 SD are presented.this antiapoptotic function, we examined the interaction
between QARS and ASK1 in the presence or absence of
glutamine. In both cases, we detected a weak interaction
between WT QARS and ASK1, but this interaction was
not significantly weakened by p.Gly45Val, p.Tyr57His,
p.Arg403Trp, or p.Arg515Trp (Figure S4 and data not
shown). Thus, these variants most likely compromise
QARS function by their direct effects on enzymatic activity.
Among the eight aaRSs of the MSC, aspartyl-tRNA syn-
thetase (encoded by DARS) and lysyl-tRNA synthetase
(encoded by KARS) have previously been associated with
human diseases. KARS mutations were first identified in
one person with Charcot-Marie-Tooth disease24 and were
more recently uncovered in three independent consan-
guineous families affected by nonsyndromic hearing
loss.25 Mutations in DARS have been reported to cause
leg spasticity and hypomyelination in the brain stem and
spinal cord.15 Surprisingly, the progressive microcephaly
and diffuse cerebral-cerebellar atrophy caused by QARS
mutations are distinct from the disorders caused by KARS
or DARS mutations or by mutations in other genes encod-
ing cytoplasmic tRNA synthetases (these latter disorders
typically manifest as peripheral neuropathies;14,16 see the
Introduction for more details), suggesting that mutations
in QARS cause a different syndrome.556 The American Journal of Human Genetics 94, 547–558, April 3, 2The progressive microcephaly and diffuse cerebral-
cerebellar atrophy associated with QARS mutations show
certain similarity to PCH with progressive microcephaly,
caused by mutations in RARS2,9,21 TSEN54,7 and
SEPSECS,8 all three of which encode proteins involved in
or upstream of tRNA aminoacylation (see the Introduction
for more details). However, the cerebral cortex and cere-
bellar vermis are primarily affected in individuals carrying
QARSmutations, and onlymild atrophy of cerebellar hemi-
spheres has been observed; this is distinct from PCH, in
which the cerebellumandbrain stemaremost affected, sug-
gesting a syndrome specifically associated with mutations
inQARS. Our results highlight the critical roles ofQARSdur-
ing CNS development and the diverse disease phenotypes
caused by loss of function of tRNA synthetases in humans.Supplemental Data
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